Related Experiment Video
Updated: Jun 29, 2025
Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
Published on: January 7, 2019
Recent progress in combination therapy of oncolytic vaccinia virus
Seyedeh Nasim Mirbahari1,2, Miles Da Silva3,4, Abril Ixchel Muñoz Zúñiga5,6
1Faculty of Sciences and Advanced Technologies in Biology, University of Science and Culture, Academic Center for Education, Culture and Research (ACECR), Tehran, Iran.
Abstract:
In recent years, oncolytic viruses have emerged as promising agents for treating various cancers. An oncolytic virus is a non-pathogenic virus that, due to genetic manipulation, tends to replicate in and cause lysis of cancerous cells while leaving healthy cells unaffected. Among these viruses, vaccinia virus is an attractive platform for use as an oncolytic platform due to its 190 Kb genome with a high capacity for encoding therapeutic payloads. Combining oncolytic VV therapy with other conventional cancer treatments has been shown to be synergistic and more effective than monotherapies. Additionally, OVV can be used as a vector to deliver therapeutic payloads, alone or in combination with other treatments, to increase overall efficacy. Here, we present a comprehensive analysis of preclinical and clinical studies that have evaluated the efficacy of oncolytic vaccinia viruses in cancer immunotherapy. We discuss the outcomes of these studies, including tumor regression rates, overall survival benefits, and long-term responses. Moreover, we provide insights into the challenges and limitations associated with oncolytic vaccinia virus- based therapies, including immune evasion mechanisms, potential toxicities, and the development of resistance.
Insights
Oncolytic vaccinia viruses show promise in cancer immunotherapy by selectively destroying cancer cells. This analysis reviews studies on their efficacy, benefits, and challenges in treating various cancers.
Area of Science:
- Oncology
- Virology
- Immunotherapy
Background:
- Oncolytic viruses are engineered to target and lyse cancer cells, sparing healthy ones.
- Vaccinia virus (VV) is a versatile platform for oncolytic virotherapy due to its large genome capacity for therapeutic payloads.
Purpose of the Study:
- To comprehensively analyze preclinical and clinical studies on the efficacy of oncolytic vaccinia viruses (OVV) in cancer immunotherapy.
- To discuss the outcomes, challenges, and limitations of OVV-based cancer treatments.
Main Methods:
- Systematic review and analysis of published preclinical and clinical research on oncolytic vaccinia viruses.
- Evaluation of efficacy metrics including tumor regression, survival benefits, and long-term responses.
Main Results:
- Oncolytic vaccinia virus therapy, often combined with other treatments, demonstrates synergistic effects and improved efficacy.
- Studies indicate potential for tumor regression, enhanced overall survival, and sustained responses in cancer patients.
Conclusions:
- Oncolytic vaccinia viruses represent a promising approach in cancer immunotherapy, offering a platform for targeted cancer cell lysis and therapeutic payload delivery.
- Further research is needed to address challenges such as immune evasion, potential toxicities, and resistance mechanisms to optimize OVV-based therapies.
Related Concept Videos
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
01:27Tumor Immunotherapy
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:56Treatment Resistant Cancers
01:28Preclinical Development: Overview
01:51Vaccinations